MIRA Pharmaceuticals Achieves 100% Reversal Of Neuropathic Pain With Oral Ketamir-2 In A Rat Study, Outperforming Oral Ketamine And Showcasing Its Potential As A Significant Treatment For Neuropathic Pain, Setting The Stage For Further Clinical Trials.
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals has reported a 100% reversal of neuropathic pain in a rat study using its oral Ketamir-2, outperforming oral ketamine. This success highlights Ketamir-2's potential as a significant treatment for neuropathic pain and sets the stage for further clinical trials.
August 23, 2024 | 8:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MIRA Pharmaceuticals' oral Ketamir-2 has shown a 100% reversal of neuropathic pain in a rat study, outperforming oral ketamine. This positions Ketamir-2 as a promising treatment for neuropathic pain, potentially leading to further clinical trials.
The successful rat study with Ketamir-2 suggests a strong potential for MIRA Pharmaceuticals to advance in the neuropathic pain treatment market. This could lead to increased investor interest and a positive impact on the stock price as the company moves towards clinical trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100